Unique ID issued by UMIN | UMIN000022257 |
---|---|
Receipt number | R000025509 |
Scientific Title | Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentration |
Date of disclosure of the study information | 2016/05/16 |
Last modified on | 2017/05/14 16:51:32 |
Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentration
Prediction of the lenalidomide toxicity by measuring its plasma concentration
Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentration
Prediction of the lenalidomide toxicity by measuring its plasma concentration
Japan |
multiple myeloma
Hematology and clinical oncology |
Malignancy
NO
Lenalidomide (Len) has significant clinical activity in patients with multiple myeloma (MM) and it is usually administered at a dose of 25 mg daily. However, it is important to determine the most suitable dosage on patient individually. The aim of this study is to investigate the relationship between pharmacokinetic variability of lenalidomide and its toxicity and therapeutic efficacy.
Pharmacokinetics
Hematological and non-hematological adverse event
Continuity of initial dosage, Hematological response
Observational
Not applicable |
Not applicable |
Male and Female
Multiple myeloma patient who received lenalidomide and dexamethasone
Multiple myeloma patient who recieved anti-cancer drugs in additon to lenalidomide
30
1st name | |
Middle name | |
Last name | Chihiro Shimazaki |
Japan Community Health care Organization Kyoto Kuramaguchi Medical Center
Department of Hematology
27 koyamashimohusa-cho, Kita-ku, Kyoto
075-441-6101
shimazaki-chihiro@kyoto.jcho.go.jp
1st name | |
Middle name | |
Last name | Shin-ichi Fuchida |
Japan Community Health care Organization Kyoto Kuramaguchi Medical Center
Department of Hematology
27 koyamashimohusa-cho, Kita-ku, Kyoto
075-441-6101
sfuch0614@gaia.eonet.ne.jp
Japan Community Health care Organization Kyoto Kuramaguchi Medical Center
Japan Community Health care Organization Kyoto Kuramaguchi Medical Center
Self funding
Division of Biological Sciences Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University
NO
独立行政法人地域医療機能推進機構京都鞍馬口医療センター
2016 | Year | 05 | Month | 16 | Day |
Unpublished
Completed
2013 | Year | 03 | Month | 01 | Day |
2013 | Year | 07 | Month | 10 | Day |
This study was started on October 24, 2011. All multiple myeloma patients treated in Kyoto Kuramaguchi Medical Center and compatible to eligibility criterion are included in this study. Plasma concentration of lenalidomide is evaluated.
2016 | Year | 05 | Month | 10 | Day |
2017 | Year | 05 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025509
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |